Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock (FLUDRO)
Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response, Gastric Mucosal Perfusion and Arterial Stiffness in Septic Shock
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Rennes, France, 35033
- Service de Réanimation Chirurgicale - Hôpital de Pontchaillou
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients over than 18 years old
- Septic shock
- Haemodynamic stability (mean arterial pressure between 70 and 80 mmHg) for at least 1 hour, with a norepinephrine dose less than 0,5 µg/kg/min
- Written informed consent
Exclusion Criteria:
- Corticotherapy
- Known allergy to Fludrocortisone
- Esophageal or gastric disease
- Pregnant woman
- Inclusion in another clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: 2
Placebo
|
1 tablet of placebo per os
|
|
Experimental: 1
Fludrocortisone
|
50 µg of fludrocortisone per os
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Norepinephrine-mean arterial pressure dose-response relationship
Time Frame: 1.5 h after administration
|
1.5 h after administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Systolic and diastolic arterial pressures, heart rate, cardiac output, systemic vascular resistances
Time Frame: During 3 h after administration
|
During 3 h after administration
|
|
Central aortic pressures, Augmentation Index (Aix).
Time Frame: During 3 h after administration
|
During 3 h after administration
|
|
Arterial stiffness: Carotid-femoral Pulse Wave Velocity
Time Frame: During 3 h after administration
|
During 3 h after administration
|
|
Humeral diameter and distensibility
Time Frame: During 3 h after administration
|
During 3 h after administration
|
|
Gastric mucosal perfusion
Time Frame: During 3 h after administration
|
During 3 h after administration
|
|
Plasma electrolytes, blood glucose, serum creatinine
Time Frame: Each hour during 3 h after administration
|
Each hour during 3 h after administration
|
|
Plasma renin, aldosterone, norepinephrine, epinephrine, fludrocortisone, TNF alpha concentrations
Time Frame: Each hour during 3 h after administration
|
Each hour during 3 h after administration
|
|
Urinary electrolytes excretion
Time Frame: Each hour during 3 h after administration
|
Each hour during 3 h after administration
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Bruno LAVIOLLE, MD, Rennes University Hospital
Study record dates
Study Major Dates
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EudraCT 2007-007971-18
- CIC0203/082
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.